Seres therapeutics issues statement regarding u.s. fda's march 12, 2020 safety alert related to use of fecal microbiota transplantation

Seres therapeutics issues statement regarding u.s. food and drug administration’s march 12, 2020 safety alert related to use of fecal microbiota transplantation.seres therapeutics inc - fda alert is related to unapproved fmt and does not impact co's investigational microbiome therapeutic candidates.seres therapeutics- on mar 12, fda stated became aware of 6 infections caused by epec, stec that have occurred following investigational use of fmt.seres therapeutics- fda suspects infections were due to transmission of pathogenic organisms from fmt product supplied by stool bank co based in u.s..seres - believes donor, product screening are necessary but insufficient to minimize infection risk for donor-derived microbiome, fmt products.
MCRB Ratings Summary
MCRB Quant Ranking